---
title: "RCKT Q1'26 Earnings: revenue estimate is 0 USD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285060856.md"
description: "RCKT (Rocket Pharmaceuticals, Inc.) is set to announce its Q1'26 results on May 11, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.41) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported—————Revenue Estimate6.23 M—312.50 K——Revenue Surprise-100.00%-100.00%EPS Reported(0.56)(0.62)(0.45)(0.38) EPS Estimate(0.61)(0.55)(0.50)(0.44)(0.41) EPS Surprise+8.34%-13.15%+9.24%+14.18%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc."
datetime: "2026-05-04T11:00:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285060856.md)
  - [en](https://longbridge.com/en/news/285060856.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285060856.md)
---

# RCKT Q1'26 Earnings: revenue estimate is 0 USD

RCKT (Rocket Pharmaceuticals, Inc.) is set to announce its Q1'26 results on May 11, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).

For Q1'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.41) USD. Learn more details at .

**Revenue & EPS values are provided in USD**

Q1'25

Q2'25

Q3'25

Q4'25

Q1'26

**Revenue Reported**

—

—

—

—

—

**Revenue Estimate**

6.23 M

—

312.50 K

—

—

**Revenue Surprise**

\-100.00%

\-100.00%

**EPS Reported**

(0.56)

(0.62)

(0.45)

(0.38)

**EPS Estimate**

(0.61)

(0.55)

(0.50)

(0.44)

(0.41)

**EPS Surprise**

+8.34%

\-13.15%

+9.24%

+14.18%

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

### Related Stocks

- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)